Systemic pharmacokinetics following intravitreal injections of ranibizumab, bevacizumab or aflibercept in patients with neovascular AMD

What is the evidence for systemic effects of intravitreal anti-VEGF agents, and should we be concerned?

(2013) Robert L Avery   BRITISH JOURNAL OF OPHTHALMOLOGY

A randomised double-masked trial comparing the visual outcome after treatment with ranibizumab or bevacizumab in patients with neovascular age-related macular degeneration

(2013) Ilse Krebs et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Plasma levels of vascular endothelial growth factor before and after intravitreal injection of bevacizumab, ranibizumab and pegaptanib in patients with age-related macular degeneration, and in patients with diabetic macular oedema

(2013) Claus Zehetner et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Intravitreal Injection of Ranibizumab for Treatment of Age-Related Macular Degeneration: Effects on Serum VEGF Concentration

(2013) Xiaoya Gu et al.   CURRENT EYE RESEARCH

Comparison of the Effect of Unilateral Intravitreal Bevacizumab and Ranibizumab Injection on Diabetic Macular Edema of the Fellow Eye

(2013) Berker Bakbak et al.   JOURNAL OF OCULAR PHARMACOLOGY AND THERAPEUTICS

Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial

(2013) Usha Chakravarthy et al.   LANCET

Ranibizumab versus Bevacizumab for Neovascular Age-related Macular Degeneration: Results from the GEFAL Noninferiority Randomized Trial

(2013) Laurent Kodjikian et al.   OPHTHALMOLOGY

Intraocular Pharmacokinetics of Ranibizumab Following a Single Intravitreal Injection in Humans

(2012) Tim U. Krohne et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY

Binding and neutralization of vascular endothelial growth factor (VEGF) and related ligands by VEGF Trap, ranibizumab and bevacizumab

(2012) Nicholas Papadopoulos et al.   ANGIOGENESIS

Ranibizumab and Bevacizumab for Treatment of Neovascular Age-related Macular Degeneration

(2012) Daniel F. Martin et al.   OPHTHALMOLOGY

Ranibizumab versus Bevacizumab to Treat Neovascular Age-related Macular Degeneration

(2012) Usha Chakravarthy et al.   OPHTHALMOLOGY

The Effect of Pre-Analytical Variability on the Measurement of MRM-MS-Based Mid- to High-Abundance Plasma Protein Biomarkers and a Panel of Cytokines

(2012) Adriana Aguilar-Mahecha et al.   PLoS One

CEREBROVASCULAR ACCIDENTS IN PATIENTS TREATED FOR CHOROIDAL NEOVASCULARIZATION WITH RANIBIZUMAB IN RANDOMIZED CONTROLLED TRIALS

(2012) Neil M. Bressler et al.   RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES

Vascular endothelial growth factor plasma levels before and after treatment of neovascular age-related macular degeneration with bevacizumab or ranibizumab

(2011) Ângela M. Carneiro et al.   ACTA OPHTHALMOLOGICA

Comparing protein VEGF inhibitors: In vitro biological studies

(2011) Lanlan Yu et al.   BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

(2011)   NEW ENGLAND JOURNAL OF MEDICINE

Plasma levels of vascular endothelial growth factor and pigment epithelium-derived factor before and after intravitreal injection of bevacizumab

(2010) K. Matsuyama et al.   BRITISH JOURNAL OF OPHTHALMOLOGY

Adverse effects of anticancer agents that target the VEGF pathway

(2009) Helen X. Chen et al.   Nature Reviews Clinical Oncology

Intraocular Pharmacokinetics of Bevacizumab After a Single Intravitreal Injection in Humans

(2008) Tim U. Krohne et al.   AMERICAN JOURNAL OF OPHTHALMOLOGY